Delta-sleep-inducing peptide reduces CRF-induced corticosterone release

Area of Science:

• Neuroendocrinology
• Peptide research
• Stress physiology

Background:

• Delta-sleep-inducing peptide (DSIP) is a nonapeptide known for its sleep-modulating effects.
• DSIP has also been anecdotally reported to possess stress-reducing properties.
• The precise mechanisms underlying DSIP's non-sleep related activities require further elucidation.

Purpose of the Study:

• To investigate the effect of DSIP on the stress response pathway.
• To determine if DSIP influences the release of corticosterone stimulated by corticotropin-releasing factor (CRF).
• To ascertain the level at which DSIP might exert its influence within the hypothalamic-pituitary-adrenal (HPA) axis.

Main Methods:

• Adult male rats were utilized for the study.
• Rats were pre-treated with a combination of chlorpromazine, morphine, and pentobarbital.
• Intravenous injections of varying doses of DSIP (5-30 µg/kg) were administered.
• Corticosterone levels were measured following stimulation with CRF.
• The effect of DSIP on adrenocorticotropic hormone (ACTH)-stimulated corticosterone release was also assessed.

Main Results:

• DSIP administration resulted in a significant reduction in corticosterone levels in a dose-dependent manner (5-30 µg/kg).
• DSIP did not alter corticosterone release when stimulated by adrenocorticotropic hormone (ACTH).
• The observed attenuation of corticosterone release was specific to the CRF-stimulated pathway.

Conclusions:

• DSIP attenuates the effects of CRF on corticosterone release.
• The mechanism of action appears to be at the pituitary level, inhibiting CRF's stimulatory effect.
• DSIP demonstrates potential as a modulator of the HPA axis, specifically targeting CRF signaling for stress reduction.